Purine nucleoside antimetabolites in development for the treatnment of cancer

Current Opinion in Investigational Drugs

Volumn 5, Issue 6, 2004, Pages 592-596

  Parker, William B ^a   Secrist III, John A ^a   Waud, William R ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

8 chloroadenosine; BCX 1777; Cancer; Clofarabine; Gene therapy of cancer; Nelarabine; Purine nucleoside

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; NEW DRUG; PURINE NUCLEOSIDE;

ANIMAL; CHEMISTRY; GENETICS; HUMAN; NEOPLASM; REVIEW;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; PURINE NUCLEOSIDES;

EID: 4043137442     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA, Allegra CJ, Johnston PG: Antimetabolites. Cancer Chemother Biol Response Modif (1999) 18:1-38.
2. Plunkett W, Gandhi V: Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif (2001) 19:21-45.
3. Elgemeie GH: Thioguanine, mercaptopurine: Their analogs and nucleosides as antimetabolites. Curr Pharm Design (2003) 9(31):2627-2642.
4. Johnson SA: Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother (2001) 2(6):929-943.
5. Nabhan C, Gartenhaus RB, Tallman MS: Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: Dawn of a new era. Leuk Res (2004) 28(5):429-442.
6. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA 3rd: Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem (1992) 35(2):397-401.
7. Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd: Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids (2000) 19(1-2):447-460.
8. Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol (1999) 43(3):233-240.
9. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA (1992) 89(7):2970-2974.
10. Reichelova V, Liliemark J, Albertioni F: Liquid chromatographic study of acid stability of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2′-deoxyadenosine and related analogues. J Pharm Biomed Anal (1995) 13(4-5):711-714.
11. Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA 3rd, Bennett LL Jr: Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res (1991) 51(9):2386-2394.
12. Xie C, Plunkett W: Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res (1995) 55(13):2847-2852.
13. Xie KC, Plunkett W: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl) adenine. Cancer Res (1996) 56(13):3030-3037.
14. Bennett LL Jr, Vail MH, Chumley S, Montgomery JA: Activity of adenosine analogs against a cell culture, line resistant to 2-fluoroadenine. Biochem Pharmacol (1966) 15:1719-1728.
15. Sternberg A: Clofarabine, Bioenvision/ILEX. Curr Opin Invest Drugs (2003) 4(12):1479-1487.
16. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103(3):784-789.
17. Markert ML: Purine nucleoside phosphorylase deficiency. Immunodefic Rev (1991) 3(1):45-81.
18. Montgomery JA: Purine nucleoside phosphorylase: A target for drug design. Med Res Rev (1993) 13(3):209-228.
19. Schramm VL: Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta (2002) 1587(2-3):107-117.
20. Reist EJ, Goodman L: Synthesis of 9-β-D- arabinofuranosylguanine. Biochemistry (1964) 3(1):15-18.
21. Verhoef V, Fridland A: Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res (1985) 45(8):3646-3650.
22. Ullman B, Martin DW Jr: Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest (1984) 74(3):951-955.
23. Cohen A, Lee JW, Gelfand EW: Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood (1983) 61(4):660-666.
24. Shewach DS, Daddona PE, Ashcraft E, Mitchell BS: Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res (1985) 45(3):1008-1014.
25. Rodriguez CO Jr, Stellrecht CM, Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood (2003) 102(5):1842-1848.
26. Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res (2002) 62(11):3100-3105.
27. Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W: Cytotoxicity, metabolism, and mechanisms of action of 2′p,2′-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res (1995) 55(7):1517-1524.
28. Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ: Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol (1998) 16(11):3607-3615.
29. Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO Jr, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ: Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol (2001) 19(8):2142-2152.
30. Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V: Pharmacokinetics of nelarabine and 9-β-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol (2000) 18(5):995-1003.
31. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ: Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: A case report and review of the literature. Cancer (1999) 85(1):58-64.
32. Cho-Chung YS: Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy. Cancer Res (1990) 50(22):7093-7100.
33. Cho-Chung YS, Clair T, Tortora G, Yokozaki H: Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol Ther (1991) 50(1):1-33.
34. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST: 8-Chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res (2001) 61(14):5474-5479.
35. Lange-Carter CA, Vuillequez JJ, Malkinson AM: 8-Chloroadenosine mediates 8-chloro-cyclic AMP-induced down-regulation of cyclic AMP-dependent protein kinase in normal and neoplastic mouse lung epithelial cells by a cyclic AMP-independent mechanism. Cancer Res (1993) 53(2):393-400.
36. Van Lookeren Campagne MM, Villalba Diaz F, Jastorff B, Kessin RH: 8-Chloroadenosine 3′,5′-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. Cancer Res (1991) 51(6):1600-1605.
37. Taylor CW, Yeoman LC: Inhibition of colon tumor cell growth by 8-chloro-cAMP is dependent upon its conversion to 8-chloro-adenosine. Anticancer Drugs (1992) 3(5):485-491.
38. Halgren RG, Traynor AE, Pillay S, Zell JL, Heller KF, Krett NL, Rosen ST: 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood (1998) 92(8):2893-2898.
39. Bennett LL Jr, Chang CH, Allan PW, Adamson DJ, Rose LM, Brockman RW, Secrist JA III, Shortnacy A, Montgomery JA: Metabolism and metabolic effects of halopurine nucleosides in tumor cells in culture. Nucleoside Nucleotides (1985) 4:107-116.
40. Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V: RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res (2003) 63(22):7968-7974.
41. Denny WA: Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol (2003) 2003(1):48-70.
42. Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ: In vivo gene therapy of cancer with E coli purine nucleoside phosphorylase. Hum Gene Ther (1997) 8(14):1637-1644.
43. Parker WB, Allan PW, Hassan AEA, Secrist JA III, Sorscher EJ, Waud WR: Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther (2003) 10(1):23-29.
44. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ: In vivo sensitization of ovarian tumors to chemotherapy by expression of E coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther (2000) 7(20):1738-1743.
45. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ: Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem (1998) 273(4):2322-2328.
46. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL Jr: Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol (1998) 55(10):1673-1681.
47. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM, Wang XY, Both GW, Russell PJ: Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med (2004) 6(1):43-54.